Company News


June 26, 2000

Ono Enters Collaboration with CuraGen for Functional Genomic Technologies
For further information
Ono Pharmaceutical Co., Ltd. announced that on June 21, 2000 it entered into two-year research collaboration with CuraGen Corporation, a genomics-based biotechnology company located in New Haven, Connecticut for advancing the discovery and development of pharmaceutical products, utilizing CuraGen's functional genomic technologies.

During the period, Ono will collaborate with CuraGen in applying CuraGen's platform of functional genomic technologies to identify genes influencing efficacy and safety of Ono's development compounds. CuraGen's technologies enable Ono to analyze genes which are activated by administration of compounds in vivo. By applying these functional genomic technologies to drug discovery research, Ono may identify specific genes related to efficacy or toxicity of compounds. Based on an activation potency of those genes, or by predicting changes in the expression of those genes, Ono believes that it can develop more efficacious and safer drugs in a more efficient way.

Functional genomic technologies of CuraGen are highly appreciated in its novelty by multi-national companies.

Additional Information
CuraGen Corporation

Founded: 1991
Location: New Haven, Connecticut, the US
Total Shareholders' equity: $42,475,193 (as of December 31, 1999)
Principal executive: Dr. Jonathan M. Rothberg
Chief Executive Officer, Chairman of the Board and President (also founder of CuraGen)
No. of shareholders: 133 (for common stock - voting)
(as of February 29, 2000)
Employees: ca. 330 (as of June 2000)
Business: Having 4 main functional genomic technologies called GeneScape, GeneCalling, SeqCalling, and PathCalling.
Advancing research and development activities for target identification, toxicity estimation, and tailor-made medicines.
Collaborations with various partners including Genentech, Pioneer Hi-Bred, Glaxo-Wellcome, Biogen, Abgenix, Hoffman-La Roche, Roche Vitamins, for identification of new genes in certain fields or for toxicity estimation, using pharmacogenomics technologies.
Having world-wide respected technologies for functional analysis of genes and proteins.